158 related articles for article (PubMed ID: 9422485)
1. Idiopathic hyperammonaemia syndrome following allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT).
Ho AY; Mijovic A; Pagliuca A; Mufti GJ
Bone Marrow Transplant; 1997 Dec; 20(11):1007-8. PubMed ID: 9422485
[TBL] [Abstract][Full Text] [Related]
2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
3. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT.
Urbano-Ispizua A; García-Conde J; Brunet S; Hernández F; Sanz G; Petit J; Bargay J; Figuera A; Rovira M; Solano C; Ojeda E; de la Rubia J; Rozman C
Haematologica; 1997; 82(6):683-9. PubMed ID: 9499667
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
6. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
8. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
9. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
10. The impact of early rehabilitation on the duration of hospitalization in patients after allogeneic hematopoietic stem cell transplantation.
Inoue J; Ono R; Okamura A; Matsui T; Takekoshi H; Miwa M; Kurosaka M; Saura R; Shimada T
Transplant Proc; 2010 Sep; 42(7):2740-4. PubMed ID: 20832579
[TBL] [Abstract][Full Text] [Related]
11. Transplant strategies for patients with myelodysplastic syndromes.
Deeg HJ
Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation.
Urbano-Ispizua A; Brunet S; Solano C; Moraleda JM; Rovira M; Zuazu J; de La Rubia J; Bargay J; Caballero D; Díez-Martín JL; Ojeda E; Pérez de Oteiza JP; Ferrá C; Espigado I; Alegre A; de La Serna J; Torres P; Riu C; Odriozola J; Rozman C; Sierra J; García-Conde J; Montserrat E;
Bone Marrow Transplant; 2001 Aug; 28(4):349-54. PubMed ID: 11571506
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Gupta V; Daly A; Lipton JH; Hasegawa W; Chun K; Kamel-Reid S; Tsang R; Yi QL; Minden M; Messner H; Kiss T
Biol Blood Marrow Transplant; 2005 Oct; 11(10):764-72. PubMed ID: 16182177
[TBL] [Abstract][Full Text] [Related]
14. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells.
Briones J; Urbano-Ispizua A; Lawler M; Rozman C; Gardiner N; Marín P; Salgado C; Féliz P; McCann S; Montserrat E
Exp Hematol; 1998 May; 26(5):415-20. PubMed ID: 9590658
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children.
Madero L; González Vincent M; Ramirez M; Quintero V; Benito A; Díaz MA
Bone Marrow Transplant; 2000 Aug; 26(3):269-73. PubMed ID: 10967564
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation for myelodysplastic syndrome (MDS).
Ingram W; Lim ZY; Mufti GJ
Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
Chan GW; Foss FM; Klein AK; Sprague K; Miller KB
Biol Blood Marrow Transplant; 2003 Dec; 9(12):753-9. PubMed ID: 14677114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
